The invention relates to the new arginine salt forms of RS-(±)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-l-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, R-(+)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, a process for their preparation and pharmaceutical formulations which comprise those arginine salt forms as the active ingredient for its use in treating microbial infections.
本发明涉及 RS-(±)-9-
氟-6,7-二氢-8-(
4-羟基哌啶-1-基)-5-甲基-l-氧代-1H,5H-苯并[i、j
]喹嗪-2-
羧酸,S-(-)-9-
氟-6,7-二氢-8-(
4-羟基哌啶-1-基)-5-甲基-1-氧代-1H,5H-苯并[i,j
]喹嗪-2-
羧酸、R-(+)-9-
氟-6,7-二氢-8-(
4-羟基哌啶-1-基)-5-甲基-1-氧代-1H,5H-苯并[i,j
]喹嗪-2-
羧酸、它们的制备工艺以及包含这些精
氨酸盐形式作为活性成分的药物制剂,用于治疗微
生物感染。